<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>G2 chromosomal sensitivity to <z:chebi fb="0" ids="3139">bleomycin</z:chebi> (30 micrograms/ml) was tested in PHA-stimulated lymphocytes of healthy subjects and in patients with familial and <z:hpo ids='HP_0003745'>sporadic</z:hpo> <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>These were multiple <z:hpo ids='HP_0100568'>endocrine neoplasias</z:hpo> (MEN) types 1, 2A and 2B, familial medullar <z:e sem="disease" ids="C0007115" disease_type="Neoplastic Process" abbrv="">thyroid cancer</z:e>, <z:e sem="disease" ids="C1406030" disease_type="Neoplastic Process" abbrv="">Recklinghausen</z:e> <z:hpo ids='HP_0001067'>neurofibromatosis</z:hpo> type I, <z:hpo ids='HP_0003745'>sporadic</z:hpo> and hereditary <z:mp ids='MP_0002018'>malignant tumors</z:mp>, and a preleukemic disorder, the <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>Control subjects were either young (15-20), middle-aged (28-49) or old (70-83 years) </plain></SENT>
<SENT sid="3" pm="."><plain>Cells from old healthy subjects and from subjects with MEN 1 showed increased sensitivity to clastogenic effects of <z:chebi fb="0" ids="3139">bleomycin</z:chebi> </plain></SENT>
<SENT sid="4" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> the remaining investigated groups were insignificantly different from controls </plain></SENT>
<SENT sid="5" pm="."><plain>Our data suggest that in contrast with recessively inherited syndromes with chromosome instability the <z:chebi fb="1" ids="25435">mutagen</z:chebi> hypersensitivity, as evaluated by the extent of chromosomal damage, is not a feature of most dominantly inherited <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> syndromes </plain></SENT>
</text></document>